Vontobel Holding Ltd. Lowers Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Vontobel Holding Ltd. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 20.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 210,385 shares of the company's stock after selling 52,817 shares during the quarter. Vontobel Holding Ltd.'s holdings in Novo Nordisk A/S were worth $14,609,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Mather Group LLC. grew its position in shares of Novo Nordisk A/S by 6.2% during the 1st quarter. Mather Group LLC. now owns 5,933 shares of the company's stock valued at $412,000 after acquiring an additional 345 shares during the period. Koshinski Asset Management Inc. lifted its stake in Novo Nordisk A/S by 27.1% in the first quarter. Koshinski Asset Management Inc. now owns 15,570 shares of the company's stock valued at $1,081,000 after purchasing an additional 3,316 shares during the last quarter. Washington Trust Advisors Inc. grew its holdings in Novo Nordisk A/S by 50.2% during the first quarter. Washington Trust Advisors Inc. now owns 778 shares of the company's stock valued at $54,000 after purchasing an additional 260 shares during the period. Mmbg Investment Advisors CO. grew its holdings in Novo Nordisk A/S by 69.7% during the first quarter. Mmbg Investment Advisors CO. now owns 29,985 shares of the company's stock valued at $2,116,000 after purchasing an additional 12,320 shares during the period. Finally, Avidian Wealth Enterprises LLC increased its position in Novo Nordisk A/S by 12.3% in the first quarter. Avidian Wealth Enterprises LLC now owns 11,000 shares of the company's stock worth $764,000 after buying an additional 1,206 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $0.77 on Friday, reaching $69.05. The stock had a trading volume of 4,047,911 shares, compared to its average volume of 7,246,407. The business's 50 day moving average is $69.82 and its two-hundred day moving average is $76.19. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $143.69. The company has a market cap of $308.31 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on NVO shares. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.